Epithelial ovarian cancer

S Lheureux, C Gourley, I Vergote, AM Oza - The Lancet, 2019 - thelancet.com
Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Epithelial ovarian cancer: evolution of management in the era of precision medicine

S Lheureux, M Braunstein… - CA: a cancer journal for …, 2019 - Wiley Online Library
Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …

N Colombo, C Sessa, A du Bois, J Ledermann… - Annals of oncology, 2019 - Elsevier
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

[HTML][HTML] Randomized trial of cytoreductive surgery for relapsed ovarian cancer

P Harter, J Sehouli, I Vergote, G Ferron… - … England Journal of …, 2021 - Mass Medical Soc
Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …

Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology

DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

S Kehoe, J Hook, M Nankivell, GC Jayson, H Kitchener… - The Lancet, 2015 - thelancet.com
Background The international standard of care for women with suspected advanced ovarian
cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to …

CA125 and ovarian cancer: a comprehensive review

P Charkhchi, C Cybulski, J Gronwald, FO Wong… - Cancers, 2020 - mdpi.com
Simple Summary CA125 has been the most promising biomarker for screening ovarian
cancer; however, it still does not have an acceptable accuracy in population-based …

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

I Vergote, CG Tropé, F Amant… - … England Journal of …, 2010 - Mass Medical Soc
Background Primary debulking surgery before initiation of chemotherapy has been the
standard of care for patients with advanced ovarian cancer. Methods We randomly assigned …

Ovarian cancer

GC Jayson, EC Kohn, HC Kitchener, JA Ledermann - The lancet, 2014 - thelancet.com
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated
death. The disease typically presents in postmenopausal women, with a few months of …